ArticleTranslational vision science & technology2026
In Vivo Evaluation of Efficacy and Safety of Oxygen-Supplemented Accelerated Scleral Cross-Linking Over Time in Young Rabbits.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of riboflavin-ultraviolet A scleral cross-linking surgery over time in vivo using an accelerated protocol with supplemental oxygen. Methods: This study compared accelerated scleral collagen cross-linking (A-SXL) plus 90% O2 (30 mW/cm2 for 3 minutes with 90% oxygen supplementation) to the traditional protocol (T-SXL; 3 mW/cm2 for 30 minutes) in young New Zealand White rabbits. The right eye underwent surgery, and the left eye served as an intraindividual control. At different time points, efficiency was evaluated through spherical equivalent refraction (SER), axial length (AL), and scleral tangent modulus, and safety was assessed via electroretinogram (ERG) and hematoxylin and eosin (H&E) staining. Results: The A-SXL+90% O2 protocol significantly preserved refractive power and inhibited axial elongation over the 3-month postoperative period, and no statistically significant differences were detected when compared with the T-SXL group (P > 0.05). Moreover, the A-SXL+90% O2 protocol led to a significant increase in scleral tangent modulus at both 1 month and 3 months post-surgery, similar to the outcomes seen with T-SXL. ERG and H&E staining revealed no evidence of retinal functional impairment or histological alterations in posterior ocular tissues (sclera, choroid, and retina) in both scleral cross-linking protocols. Conclusions: A-SXL supplemented with oxygen offers a faster, effective, and relatively safe alternative to T-SXL in vivo by demonstrating sustained biomechanical reinforcement with an acceptable safety profile. Translational Relevance: A-SXL supplemented with oxygen may be a promising therapeutic approach for scleral weakening disorders such as progressive high myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.